Pharmacokinetic and clinical evaluation of ceftazidime in neonates and premature infants

K. Sunakawa, Y. Ishizuka, S. Iwata, Y. Sato, T. Oikawa

Research output: Contribution to journalArticle

Abstract

Pharmacokinetics and clinical efficacy of ceftazidime (CAZ) were evaluated in neonates. 1. After a bolus intravenous injection of 20 mg/kg CAZ to neonates, peak serum concentrations ranged from 55.1-97.4 μg/ml with a mean half-life of 2.26 hours in neonates with a birth weight of 2,500 g or more, and from 59.3-60.7 μg/ml with half-lives ranging from 3.98 to 4.22 hours in neonates weighing less than 2,500 g at birth. In the time-course observation, it was noted that the half-life 2 days after birth was longer than half-lives observed 4 and 9 days after birth. 2. Four cases were given CAZ for treatment, and 3 cases for prophylaxis of infections, and the clinical efficacy was either excellent or good in all of the cases. Neither adverse effects nor abnormal laboratory findings were observed except rash in 1 case. 3. Intestinal flora was examined in 5 cases. It was found that the effect of CAZ was less than that of LMOX, although some delay was seen in the growth of intestinal flora. 4. There was no vitamin K deficiency in any case examined.

Original languageEnglish
Pages (from-to)2097-2107
Number of pages11
JournalJapanese Journal of Antibiotics
Volume39
Issue number8
Publication statusPublished - 1986

Fingerprint

Ceftazidime
Premature Infants
Pharmacokinetics
Newborn Infant
Parturition
Half-Life
Vitamin K Deficiency
Exanthema
Birth Weight
Intravenous Injections
Observation
Growth
Infection
Serum
Gastrointestinal Microbiome
Therapeutics

ASJC Scopus subject areas

  • Pharmacology
  • Molecular Medicine

Cite this

Sunakawa, K., Ishizuka, Y., Iwata, S., Sato, Y., & Oikawa, T. (1986). Pharmacokinetic and clinical evaluation of ceftazidime in neonates and premature infants. Japanese Journal of Antibiotics, 39(8), 2097-2107.

Pharmacokinetic and clinical evaluation of ceftazidime in neonates and premature infants. / Sunakawa, K.; Ishizuka, Y.; Iwata, S.; Sato, Y.; Oikawa, T.

In: Japanese Journal of Antibiotics, Vol. 39, No. 8, 1986, p. 2097-2107.

Research output: Contribution to journalArticle

Sunakawa, K, Ishizuka, Y, Iwata, S, Sato, Y & Oikawa, T 1986, 'Pharmacokinetic and clinical evaluation of ceftazidime in neonates and premature infants', Japanese Journal of Antibiotics, vol. 39, no. 8, pp. 2097-2107.
Sunakawa, K. ; Ishizuka, Y. ; Iwata, S. ; Sato, Y. ; Oikawa, T. / Pharmacokinetic and clinical evaluation of ceftazidime in neonates and premature infants. In: Japanese Journal of Antibiotics. 1986 ; Vol. 39, No. 8. pp. 2097-2107.
@article{9d52fd97d12046d2899af2655941f739,
title = "Pharmacokinetic and clinical evaluation of ceftazidime in neonates and premature infants",
abstract = "Pharmacokinetics and clinical efficacy of ceftazidime (CAZ) were evaluated in neonates. 1. After a bolus intravenous injection of 20 mg/kg CAZ to neonates, peak serum concentrations ranged from 55.1-97.4 μg/ml with a mean half-life of 2.26 hours in neonates with a birth weight of 2,500 g or more, and from 59.3-60.7 μg/ml with half-lives ranging from 3.98 to 4.22 hours in neonates weighing less than 2,500 g at birth. In the time-course observation, it was noted that the half-life 2 days after birth was longer than half-lives observed 4 and 9 days after birth. 2. Four cases were given CAZ for treatment, and 3 cases for prophylaxis of infections, and the clinical efficacy was either excellent or good in all of the cases. Neither adverse effects nor abnormal laboratory findings were observed except rash in 1 case. 3. Intestinal flora was examined in 5 cases. It was found that the effect of CAZ was less than that of LMOX, although some delay was seen in the growth of intestinal flora. 4. There was no vitamin K deficiency in any case examined.",
author = "K. Sunakawa and Y. Ishizuka and S. Iwata and Y. Sato and T. Oikawa",
year = "1986",
language = "English",
volume = "39",
pages = "2097--2107",
journal = "The Journal of antibiotics. Ser. B",
issn = "0368-2781",
publisher = "Japan Antibiotics Research Association",
number = "8",

}

TY - JOUR

T1 - Pharmacokinetic and clinical evaluation of ceftazidime in neonates and premature infants

AU - Sunakawa, K.

AU - Ishizuka, Y.

AU - Iwata, S.

AU - Sato, Y.

AU - Oikawa, T.

PY - 1986

Y1 - 1986

N2 - Pharmacokinetics and clinical efficacy of ceftazidime (CAZ) were evaluated in neonates. 1. After a bolus intravenous injection of 20 mg/kg CAZ to neonates, peak serum concentrations ranged from 55.1-97.4 μg/ml with a mean half-life of 2.26 hours in neonates with a birth weight of 2,500 g or more, and from 59.3-60.7 μg/ml with half-lives ranging from 3.98 to 4.22 hours in neonates weighing less than 2,500 g at birth. In the time-course observation, it was noted that the half-life 2 days after birth was longer than half-lives observed 4 and 9 days after birth. 2. Four cases were given CAZ for treatment, and 3 cases for prophylaxis of infections, and the clinical efficacy was either excellent or good in all of the cases. Neither adverse effects nor abnormal laboratory findings were observed except rash in 1 case. 3. Intestinal flora was examined in 5 cases. It was found that the effect of CAZ was less than that of LMOX, although some delay was seen in the growth of intestinal flora. 4. There was no vitamin K deficiency in any case examined.

AB - Pharmacokinetics and clinical efficacy of ceftazidime (CAZ) were evaluated in neonates. 1. After a bolus intravenous injection of 20 mg/kg CAZ to neonates, peak serum concentrations ranged from 55.1-97.4 μg/ml with a mean half-life of 2.26 hours in neonates with a birth weight of 2,500 g or more, and from 59.3-60.7 μg/ml with half-lives ranging from 3.98 to 4.22 hours in neonates weighing less than 2,500 g at birth. In the time-course observation, it was noted that the half-life 2 days after birth was longer than half-lives observed 4 and 9 days after birth. 2. Four cases were given CAZ for treatment, and 3 cases for prophylaxis of infections, and the clinical efficacy was either excellent or good in all of the cases. Neither adverse effects nor abnormal laboratory findings were observed except rash in 1 case. 3. Intestinal flora was examined in 5 cases. It was found that the effect of CAZ was less than that of LMOX, although some delay was seen in the growth of intestinal flora. 4. There was no vitamin K deficiency in any case examined.

UR - http://www.scopus.com/inward/record.url?scp=0022551174&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022551174&partnerID=8YFLogxK

M3 - Article

C2 - 3540343

AN - SCOPUS:0022551174

VL - 39

SP - 2097

EP - 2107

JO - The Journal of antibiotics. Ser. B

JF - The Journal of antibiotics. Ser. B

SN - 0368-2781

IS - 8

ER -